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Cellular processes are dictated by the active signaling of proteins relaying messages to regulate cell proliferation,
apoptosis, signal transduction and cell communications. An intricate web of protein kinases and phosphatases
are critical to the proper transmission of signals across such cascades. By governing 30–50% of all protein
dephosphorylation in the cell, with prominent substrate proteins being key regulators of signaling cascades, the
phosphatase PP2A has emerged as a celebrated player in various developmental and tumorigenic pathways,
thereby posing as an attractive target for therapeutic intervention in various pathologies wherein its activity is
deregulated. This review is mainly focused on refreshing our understanding of the structural and functional
complexity that cocoons the PP2A phosphatase, and its expression in cancers. Additionally, we focus on its
physiological regulation as well as into recent advents and strategies that have shown promise in countering the
deregulation of the phosphatase through its targeted reactivation. Finally, we dwell upon one of the key reg-
ulators of PP2A in cancer cells-cellular redox status-its multifarious nature, and its integration into the reactome
of PP2A, highlighting some of the significant impacts that ROS can inflict on the structural modifications and
functional aspect of PP2A.
1. Protein phosphatases
Post-translational modifications (PTMs) of proteins serve an im-
portant function in signaling cascades by limiting the activation and
counter-inhibition of moieties in response to appropriate stimuli. In a
2011 study by Khoury et al. phosphorylation modifications were
identified as the dominating experimental PTM on proteins [1]. The
three putative phosphorylation residues on proteins include serine (S),
threonine (T) and tyrosine (Y) wherein phosphoserine has emerged as
the predominant site with the highest degree of phosphorylations
amongst the three sites, followed by the two latter sites respectively [2].
Usually, the kinases donate the phosphate group, which attaches itself
to the hydroxyl (-OH) group on the amino acid residues. The activity of
kinases is countered by protein phosphatases which remove the phos-
phate group on proteins through a nucleophilic reaction in the presence
of water [3]. The protein phosphatases fall under three broad cate-
gories: the protein serine/threonine phosphatases (PSPs), phosphotyr-
osine phosphatases (PTPs) and the dual specificity phosphatases
(DUSP), which can dephosphorylate all three residues [4]. PSPs are
further subclassified into three distinct subcategories: phosphoprotein
phosphatases (PPPs), the metal-dependent protein phosphatases (PPMs)
and the aspartate-based phosphatases. Subsequent classification of PPPs
divides them into subfamilies PP1, PP2A, calcineurin and PP4-PP7,
while the PPM family which catalyses Mg2+/Mn2+ dependent depho-
sphorylations, comprises PP2C and pyruvate dehydrogenase phospha-
tases. Lastly, the aspartate-based phosphatases distinctly carry an as-
partate acid signature (DXDXT/V) and include the TFIIF-associated C-
terminal domain phosphatase/small CTD phosphatases and the halo
acid dehydrogenase (HAD) enzyme family [5]. Recently, a novel family
of phosphatases has been identified that lends itself to the depho-
sphorylation of phosphohistidine residues [6]. This phosphatase is not
well studied yet but seems to play a vital role in some cancers as well as
insulin signaling [7–9]
Compared to the serine/threonine kinases (S/T kinases), of which
there exists a vast number making up the kinome, far fewer protein S/T
phosphatases exist at a ratio of 30 phosphatases for 420 kinases [3,10].
However, protein phosphatases compensate their inadequate aggregate
through the vast number of regulatory isoform subunits that control
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their substrate specificity, and thus achieve a measurable functional
diversity that is commensurate to antagonise the activity of S/T kinases.
Early research on S/T phosphatase function was limited to studies that
focused on pharmacological inactivation of the phosphatases through
naturally occurring compounds such as the extracts obtained from the
marine toxins okadaic acid, calyculin A, tautomycin and microcystins
which can strongly inhibit the catalytic activity of PP1 and PP2A
[11–15]. In recent years however, there is a surge in the quest to
characterise these phosphatases as they exert their effects on a myriad
of proteins that are key intermediates of oncogenic and developmental
pathways. This review focuses on the latter of the two phosphatases,
PP2A as PP2A has significant precedence in that it is ubiquitously ex-
pressed in various cell types, with some of the highest expression re-
ported for its catalytic subunit in cells; and is known to orchestrate
cellular events by controlling on average 1% of all protein depho-
sphorylation events [16]. Therefore, it becomes imperative to char-
acterise the phosphatase PP2A and understand the biology sustaining
its functions towards targeting the phosphatase to its myriad of sub-
strates in the various subcellular compartments. (Table 1).
2. Serine/threonine phosphatase PP2A
The phosphatase PP2A is a critical mediator of key cellular pro-
cesses such as glycolytic, fatty acid and lipid metabolism, signal
transduction, DNA replication and mitosis, cell proliferation and
apoptosis, cytoskeletal organization, protein translation and immune
regulation [17–26]. It is ubiquitously expressed in several subcellular
compartments such as the nucleus, plasma membrane and the cyto-
plasm. PP2A is broadly derived from three structural compartments: the
scaffold A subunit (PP2A A), the regulatory B subunit (PP2A B) and the
catalytic C subunit [27]. The PP2A A and PP2A C can exist as a dimeric
complex and is considered the core enzyme, while the B regulatory
subunit can exist singularly. The trimeric complex formed upon the
binding of PP2A B to the PP2A AC core dimer comprises the active
holoenzyme complex (Fig. 1).
The catalytic subunit of PP2A (PP2A C) is ubiquitously expressed in
mammals. The full length PP2A C subunit comprises 309 amino acids.
Two isoforms of PP2A C, Cα and Cβ, are transcribed by two distinct
genes, but are highly similar in their sequence with over 97% consensus
[28]. However, despite this high degree of sequence conservation,
PP2A Cα knock out mice are embryonically lethal, suggesting that the
two isoforms are non-redundant and emphasising the importance of the
Cα isoform in embryonic development. While the Cα isoform is pre-
dominantly detected in the membrane fraction, the Cβ isoform is mostly
found in the cytosol or the nuclear fractions [27]. The highly conserved
C-terminal amino acids 304TPDYEL309 is essential for the binding of
PP2A C to the A scaffold and B regulatory subunits [29–32].
Correspondingly, the scaffold subunit of PP2A – PP2A A, also exists
as two separate isoforms transcribed by two distinct genes PPP2R1A
and PPP2R1B as Aα and Aβ subunits, which share 86% sequence
homology [33]. Both isoforms are localised in the cytoplasm. The Aα
isoform predominates with about 90% of PP2A A expressed as this
isoform. The A subunit of PP2A has distinct functions in the dimeric and
trimeric enzyme complex. While in the dimeric complex it regulates the
catalytic specificity of the enzyme, it mainly serves as a base to aid the
interaction between the core dimer, the regulatory subunit and the
enzyme substrates in the trimeric holoenzyme complex. It is also
structurally disparate in comparison to the other PP2A subunits in
comprising HEAT (Huntingtin, Elongation factor 3, PP2A A, and the
yeast kinase TOR1) repeats, named after the proteins that contain these
tandem repeats. While PP2Ac binds to the domain comprising HEAT
repeats 11–15, the regulatory subunits bind repeats 1–10. The AC core
dimer binding results in the bending of the A subunit along the loop
regions leading to the formation of a pocket that is ideal for the re-
cruitment of the substrate bound B regulatory subunit [32].
The PP2A regulatory subunits are further divided into sub-classes –
PP2A B/B55/PR55, PP2A B′/B56/PR56/PR61, PP2A B′′/PR48/PR72/
PR130 and the PP2A B′′′/PR93/PR110. The numbers associated with
these subfamilies indicate the molecular weights of the isoforms com-
prising these subunits.
The PP2A B55 subfamily consists of four distinct isoforms, the alpha
(α), beta (β), gamma (γ) and delta (δ). The B55 subfamily is distinct
from the other regulatory subfamilies in comprising WD40 repeat do-
mains which regulate substrate binding. While the functions of the B55
family members are mostly concentrated on the regulation of cytokin-
esis and mitotic activity, the B55γ and B55β isoforms are reported to be
developmentally regulated and regulate cellular events such as cytos-
keletal dynamics and cellular differentiation [34–39]. Moreover, there
also exists a tissue specific distribution of these isoforms, wherein, the
B55α and B55δ isoforms are ubiquitously expressed in almost all
mammalian tissues; however, the B55β and B55γ are more pronounced
in the brain [40,41]. The B55α isoform has also been known to play a
role in cell proliferation and survival through its regulation of one of
the focal oncoproteins in the PI3K signaling pathway, AKT/PKB, as well
as play an important role in regulating replication stress mediated
through the regulation of the DNA repair enzyme RPA2 [42,43]. In the
latter aspect, there is now a growing body of evidence indicating a
pivotal role for the B55α subunit in DNA damage response through its
regulation of substrates RPA2, Plk-1, Ku-70, ATM and γ-H2AX, which
are all key orchestrators of DNA repair [44–47]. These reports highlight
a critical role for the B55-PP2A-AC complex in cell cycle, proliferation
and DNA repair, suggesting the paramount significance of the dereg-
ulation of this complex in cancers.
The PP2A B56 subfamily has five different isoforms – the alpha (α),
beta (β), gamma (γ), delta (δ) and epsilon (ε). Their unique attributes
include the feature that this is the only subfamily whose members
might themselves be phosphorylated. Studies have indicated the im-
portance of such phosphorylation in regulating the function of PP2A
through affecting holoenzyme assembly or other yet unknown me-
chanisms [48–50]. They are also structurally distinct in that most
members have α helix structures instead of β strand repeats that are
noted for the members of the other subfamilies [31,32]. Their se-
quences are highly conserved with differences mainly apparent only in
the N and C terminal regions which lead to their differential expression
in tissues. While B56α, B56β and B56ε have been identified only in the
cytoplasm, the B56γ and B56δ isoforms are also localised to the nucleus
[27]. The B56 family isoforms have diverse functions in shaping the
cancer proteome through their regulation of key cellular processes such
as DNA repair, cellular proliferation and differentiation, apoptosis,
angiogenesis, invasion and migration [51–53].
The PR48/72/130 isoforms were first isolated from rabbit skeletal
muscle through chromatography and gel filtration. While the PR72
Fig. 1. PP2A structure and function: Serine/threonine phosphorylated proteins
interact with substrate specific B regulatory subunits, which subsequently re-
cruits the substrate protein to the core enzyme. Holoenzyme formation is sta-
bilized by the binding of the phosphorylated substrate to PP2A-B. The catalytic
subunit then proceeds to dephosphorylate the substrate. Crystal structure of
PP2A (2IAE) adapted from RCSB PDB – Cho and Xu [277].
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isoform is only expressed in the heart and skeletal muscle tissue, the
other isoforms are more ubiquitously expressed [54]. The PP2A B′′
isoforms are poorly studied. The Human Protein Atlas database reports
favourable outcome of this regulatory subunit in several cancers, al-
though some cancers such as those of liver, pancreatic and endometrial
origin predict an unfavourable outcome of their expression [55]. Their
exclusive feature includes the presence of calcium binding motifs which
in response to calcium mediated signaling can regulate the ability of
this regulatory subunit to bind the AC core dimer [56–58]. They also, in
stark contrast to the B56 subunits activate replication of simian virus 40
(SV40), and have been further reported to play a role in DNA damage
response through their regulation of Rb [59–61].
Finally, the PP2A B′′′ isoforms play a vital role in calcium signaling
through their binding of calmodulin (CaM). This subfamily is also cri-
tically dependent on ATP and the Mg2+ cation for its activation. This
family of enzymes is also reported to regulate the cell cycle as key
members of this family include the Striatin and S/G2 nuclear auto an-
tigen (SG2NA) proteins [62].
3. PP2A is a bona-fide tumor suppressor
Evidence suggesting a tumor suppressive role for PP2A originates
from the observations that, in a myriad of cancers, the phosphatase
PP2A is inactivated through deep-seated genetic mutations as well as
post-translational modifications. The COSMIC database identifies the
PP2A Aα subunit harbouring the highest number of mutations amongst
all the PP2A subunits with a database recognizing an increased pro-
pensity for mutations in gynaecological cancers [63–73]. The vast
majority of the somatic mutations in PP2A Aα are concentrated in the
HEAT repeat 5 region, with the two most common mutational hotspots
represented by R418W and P179R. The HEAT repeat 5 region holds
profound significance as it is the region that has been described on the
scaffold subunit to be essential for binding with the B and C subunits of
PP2A for holoenzyme assembly. These mutations generally result in
holoenzyme disruption as a result of diminished binding to the catalytic
C and the regulatory B subunits. Indeed, in-vitro analysis to study the
binding competence of the different B regulatory subunits of PP2A
verified defective binding of the P179A, R183A, R183E and W257A
point mutants [74,75]. Cancer related mutations in the PP2A Aα sub-
units usually render the gene product haploinsufficient. For example,
point mutations targeting the E64 glutamate residue, E64D and E64G
substitutions, result in the inability of the scaffold subunit to bind the
regulatory B56α and B56δ subunits of PP2A, respectively [76,77].
Moreover, these mutations also sensitized mice harbouring the het-
erozygous E64 mutation to carcinogenic agents like benzopyrene as
well as augmented the frequency of developing lung cancer when
crossed with a KRAS G12D mutant mouse [76,78]. Apart from muta-
tions, downregulation of PP2A Aα protein expression has also been
observed in a couple of reports in gliomas and breast cancer, although
the impact and mechanism of this phenotype is poorly understood
[79,80].
Intriguingly, very few reports highlighting mutations in the PP2A
Aβ counterpart have been reported as yet. The first reports discovering
mutation in the 11q23 PPP2R1B locus was identified by Wang et al in
1998 in lung and colon carcinomas [81]. Subsequent reports of somatic
mutations of this PP2A Aβ isoform emerged in neoplasms ranging from
breast, haematopoietic tumors and parathyroid adenomas, albeit sug-
gesting very little impact of these mutations on tumor progression
[77,82,83]. Conversely, Takagi et al. do report that there is a significant
effect of mutations in PP2A Aβ in colorectal cancer, wherein they found
diminished phosphatase binding capacity in ~13% of clinical samples
tested. However, they have been careful to suggest that the LOH in the
11q23 locus leading to tumor progression may be contributed through
mutations in other genes such as ATM, CHK1, MLL1 and DDX10, which
have been previously reported to be notably mutated in tumors. The
relatively low level of mutation frequency for this isoform of PP2A A is
not well elucidated and it is likely that advances in sequencing and
mapping of alterations will shine some light on this conundrum in the
near future. Loss of protein expression of PP2A Aβ in ~50% cancer cell
lines, when matched against their counterpart primary normal human
epithelial cells, also suggests an important role for the PP2A Aβ isoform
in tumor suppression [84]. Finally, an in-vitro study has also suggested
a significant role for PP2A Aβ in promoting transformation of immortal
cells through loss of phosphatase activity resulting in activation of the
substrate protein RalA GTPase via its phosphorylation at the S183/194
residues [85]. Recently small molecule activators of PP2A that bind to
the A scaffold subunit of PP2A have demonstrated great prowess as an
attractive chemotherapeutic intervention that is tailored to mediating
cancer cell kill via the activation of PP2A phosphatase, further high-
lighting the pivotal role of the phosphatase in mediating tumor re-
pression [86–88].
Many of the substrates of the B regulatory subunits of PP2A are key
proteins that are involved in key tumor signal transduction pathways.
This list includes but is not limited to ERK, AKT, p53, c-Myc, Bcl-2, NF-
κB, STAT-3, Rb, E2F1, Cyclins, PLK-1 Chk1 and ATM which are all key
regulators of cellular processes in human cancers. Recent studies have
helped in elucidating the interactome of phosphatases including PP2A
boosting the impact of loss of substrate specific B regulatory subunits in
promoting cancer development [45,52,89]. Several B55 and B56 reg-
ulatory subunits have also been reported to have altered expression or
mutations in numerous cancers. These include but are not limited to
B55α, B55β, B55γ, B55ε, B56α and B56γ [47,90–103]. It is evident that
these loss of function mutations of the regulatory subunits have a vast
impact on the cancer proteome as it directly impacts the stability and/
or activity of its specific substrate.
Complementary regulation of B subunit activity is directly under the
purview of the endogenous inhibitor of PP2A - CIP2A - which has been
shown to bind the B55 and B56 regulatory isoforms and inhibit sub-
strate specific dephosphorylation by the PP2A phosphatase [104–106].
It is interesting to note that CIP2A is found commonly overexpressed in
a myriad of cancer cells, most strikingly correlating with aggressive
disease outcome [106–115]. The Human Protein Atlas database vali-
dates the strong correlation of CIP2A overexpression in cancers with
unfavourable prognosis [55]. Serendipitously, targeting this node to
treat cancers overexpressing CIP2A has presently emerged as a strong
small molecule therapeutic intervention. Indeed, erlotinib derivatives
TD-19 and TD-52 have shown promising results in vitro in aggressive
breast, lung and hepatocellular carcinomas, and it is likely that their
development will be accelerated in the future for treating CIP2A
overexpressing cancers [116–118]. These reports further support the
designation of PP2A as a bona-fide tumor suppressor.
Not many mutations have been reported for the catalytic PP2A C
subunit. Downregulation of the catalytic subunit of PP2A has been re-
ported in some haematopoietic, gastric and prostate cancers [119–124].
Sens et al. have reported that PP2A inactivation may also result from
the haploinsufficient loss of PPP2R4 (PTPA) gene which enhances PP2A
activity by binding with the catalytic subunit of PP2A [125]. Further-
more, overexpression or deregulated activation of the endogenous in-
hibitor SET/I2PP2A is also frequently observed in cancers [126–136].
The SET protein has been reported to directly interact with the catalytic
subunit of PP2A, thereby impeding its activity [137]. In-vitro binding
and binding sequence mapping of the SET protein to the catalytic
subunit has been recently demonstrated [138]. Indeed, reactivation of
PP2A through inhibition of SET by the compounds FTY720 and OP-449
is emerging as an attractive therapeutic intervention to combat tumors
overexpressing SET [109,139–146].
4. Regulation of PP2A activity
Several post translational modifications have been identified that
are key regulators of PP2A activity and thereby critically modify the
landscape of the proteome (Fig. 2).
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One of the earliest modifications studied was the binding of the
SV40 to the scaffold A subunit of PP2A, thereby leading to disruption of
the holoenzyme assembly and correspondingly its activity [147–150].
The small t antigen of SV40 polyoma virus has been demonstrated to
bind the Aα subunit of PP2A between HEAT repeats 3–7 displacing the
interaction of the core dimer with the substrate bound PP2A B subunit,
through both in vitro and in vivo experiments [74,147,151–153]. The
SV40 ST antigen itself has two conserved zinc binding motifs that help
in the stabilisation of its binding to the PP2A core dimer. However,
while the second zinc motif has been elegantly shown to interact with
the scaffold subunit, wherein the proline 132 residue binds between the
tryptophan 140 and phenylalanine 141 and was determined to be in-
dispensable for A-ST interaction, it is thought that the first zinc motif
binds close to the active site of the catalytic subunit of PP2A subunit
suggesting that it may alter the binding of PP2A C with the substrate
bound regulatory B subunit.
Most post-translational modifications known to alter the activity of
PP2A have been identified on the catalytic C subunit of PP2A. Four
different types of PTM have been identified to date. These include the
carboxymethylation, phosphorylation, nitration and endogenous in-
hibition of PP2A through SET. The C-terminal region of the catalytic
subunit is highly conserved amongst the serine threonine protein
phosphatases. This tail region is critically positioned as a wedge be-
tween the A and B subunits. The 6 terminal residues 304T-P-D-Y-F-L309
is subject to both phosphorylation and methylation modifications that
can regulate the catalytic activity of PP2A [154–159].
L309 is subject to reversible methylation by the activity of two
enzymes LCMT1 (leucine carboxyl methyltransferase) and PME-1
(phosphatase methylesterase) [160–164]. L309 methylation has been
demonstrated to be important for holoenzyme assembly and interaction
of the core dimer especially with the B55 regulatory subunit, though
some studies do argue that this methylation also enhances the docking
affinity of the B56 regulatory subunit to the AC heterodimer. Cho et al.
have tried to explain the regulatory mechanism through which me-
thylation aids holoenzyme formation through structural docking studies
[32]. They report that the negatively charged carboxyl terminus of the
PP2A C subunit usually docks beside the 62EDE64 and E101 amino acid
residues of the scaffold subunit which already contributes to a highly
negatively charged microenvironment in this region. Therefore, neu-
tralisation of the negative charge on the carboxyl terminus could relieve
the negative charge in the microenvironment and promote its docking
to the scaffold and B regulatory subunits. In this context, there is also an
important role for the Protein Phosphatase 2 Phosphatase Activator
(PTPA) in promoting both the catalytic activity of PP2A as well as
methylation of the C-terminus of PP2A C by LCMT1. This is achieved by
direct binding of PTPA to PP2A C causing the catalytic subunit to un-
dergo a conformational change that helps orient phosphorylated sub-
strate proteins to bind to the active site as well as cooperates with ATP
to chelate metal ions that ensures the assignment of the apposite metal
ions necessary for the serine/threonine phosphatase activity of PP2A
[165]. Intriguingly the association of PTPA with PP2A C also promotes
the methylation of the L309 residue of PP2A C through the action of
LCMT-1 and it has been suggested that PP2A C bound PTPA interacts
with LCMT1 within the same region [166]. Methylation of L309 PP2A C
is reversed by the protein phosphatase methylesterase enzyme PME-1.
It is important to note that PME-1 which facilitates the demethylation
of the PP2A C subunit also directly impacts its catalytic activity by
displacing the Mn2+ cations of PP2A C that are essential for its catalytic
activity. Moreover, the hydrophobic M335 residue of PME-1 prevents
reloading of the Mn2+ ions into the active site of the enzyme [167]. A
recent study has also suggested a role for the scaffold A subunit of PP2A
to facilitate methylation of PP2A by three mechanisms: (i) alteration of
the conformation of the catalytic subunit causing more amenable
binding of PP2A C to LCMT-1, (ii) restricting the movement of the
catalytic subunit such that its rate of entry within the active binding
pocket of LCMT-1 is augmented and (iii) extending weak electrostatic
interactions through its positively charged R183 and R258 residues onto
the negatively charged LCMT-1 surface facilitating its interaction with
PP2A C by acting as a scaffold [168].
Phosphorylation of the C-terminal region of the catalytic subunit of
PP2A has been identified on Y307 and T304 residues. The Y307 phos-
phorylation, in particular, has been demonstrated to inhibit the inter-
action of PP2A C with the B' regulatory subunit of PP2A by impeding
the interaction of the tyrosine residue with V257 residue of the B'γ1
regulatory subunit of PP2A. Moreover, it also seems to have an impact
on L309 demethylation by restricting access of the catalytic subunit to
the LCMT1 pocket, thereby impairing holoenzyme assembly, and con-
sequently leading to inactivation of PP2A. Secondly, mutagenesis stu-
dies have also suggested that T304 phosphorylation of the PP2A C tail
impacts the interaction of the core enzyme with the B55 regulatory
subunit of PP2A. Such observations, however, need to be confirmed in a
physiological setting.
Nitration of the PP2Ac subunit has also been reported to impact its
activity in certain situations. However, there is much dissonance on the
impact of peroxynitrite on the nature of PP2A activity. While some
groups argue that PP2A activity is increased through the tyrosine ni-
tration of its catalytic C subunit through its increased affinity for ho-
loenzyme assembly, one group has reported that iNOS mediated per-
oxynitrite signaling contributed to nitration in the C-terminal at the
Tyr-284 residue of PP2A C which led to the dissociation of the scaffold
A subunit, with the p97 associated PP2A catalytic subunit demon-
strating an elevated phosphatase activity extending its effect on DUSP1
[169–171].
Incidentally, post-translational modifications have also been iden-
tified on the B regulatory subunits of PP2A, particularly the PR61/B′/
B56 subunit. The B56 regulatory subunit of PP2A has been reported to
be subjected to phospho-modifications by the MAP kinase protein, ERK
which severely impacts the holoenzyme assembly, and hence activity of
PP2A [32,49]. Structural analysis illustrated the impact of ERK on the
S337 residue of the B56γ1 subunit, which was earlier delineated by
Letourneux et al. to disrupt the ABC heterodimer assembly of PP2A,
leading to the inability of the catalytic core in extending its phosphatase
activity on its bona-fide substrates. Conversely, Margolis et al. have
reported that phosphorylation of the B56δ subunit of PP2A at the N-
terminal S37 residue, enhances its activity and promotes the T138 de-
phosphorylation of Cdc25, extending its impact on the cell cycle [48].
Fig. 2. Regulation of PP2A: An assortment of post-translational modifications
and mutations can intricately affect the activity or assembly of PP2A ho-
loenzyme. Several therapeutic interventions in treating cancers and other
pathologies are dependent on the reactivation of the phosphatase PP2A through
small molecule compounds targeting the different subunits.
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Additionally, our group has recently reported the nitration of a B56
regulatory subunit isoform of PP2A as a novel post-translational mod-
ification, which significantly attenuates its activity. Low et al. describe
the tyrosine nitration of the Y289 residue of B56δ as a consequence of
the intracellular redox milieu in haematopoietic cancers which results
in the disruption of the PP2A holoenzyme assembly and the subsequent
inability of the phosphatase to extend its activity on the substrate anti-
apoptotic protein Bcl-2. These findings have now unfolded a unique
role for ROS microenvironment in addressing the fate of the tumor
landscape through its regulation of the bona-fide tumor suppressor
PP2A.
5. ROS and the regulation of PP2A
Reactive oxygen species (ROS)-as the name lends itself-are radical-
or non-radical derivatives of molecular oxygen, which are chemically
reactive through either the presence of an unpaired electron in the
outermost shell of these radicals which contributes to their reactivity,
or through their strong oxidizing capacity. Some of the biologically
relevant ROS include superoxide, hydrogen peroxide, peroxynitrite,
nitric oxide as well as peroxyl and hydroxyl radicals.
ROS have for long been dogmatically viewed as molecules that are
harmful to cellular membranes resulting in tissue injury and death
[172–174]. However, their valuable role in modulating signaling re-
sponses in pathways integral to proliferation, growth and development
has been palpable [175–188]. The two most biologically relevant
physiological sources of ROS can be attributed to the NADPH oxidases
and Mitochondrial electron transport chain [189–193]. When a single
oxygen molecule in cells gains an unpaired electron, it forms the highly
chemically reactive superoxide anion (Fig. 3). Physiologically, super-
oxide anion has two distinct fates: it is instantaneously either dis-
mutated to hydrogen peroxide through the activity of the enzyme su-
peroxide dismutase (SOD), or to reactive nitrogen species such as
peroxynitrite through its reaction with nitric oxide [194–196]. As is
evident, there is a competition between formation of hydrogen peroxide
and peroxynitrite in cells that is dictated by the balance between the
activities of the two enzymes NOS (nitric oxide synthase) and SOD. By
far, hydrogen peroxide and nitric oxide have been considered the most
extensively studied ROS species in signal transduction pathways. Phy-
siologically, these two ROS govern the balance between pro-survival
and apoptotic signaling in cells and thus are critical mediators that
impact the cancer interactome.
To fuel the high bioenergetic needs of cancer cells, they accumulate
excessive amounts of ROS by-products, which are capable of building
up toxic metabolites, leading to activation of apoptotic or necrotic
programs. To counter the redox stress mediated adverse cytotoxic ef-
fects, tumor cells step up their antioxidant reserves to maintain redox
equilibrium. The impact of ROS on cellular physiology is also governed
by the nature and concentration of the ROS species encountered as well
as the subcellular compartment where the effect is sustained. In gen-
eral, a high concentration of cellular ROS causes indiscriminate damage
to biomembranes ensued by activation of apoptotic and necrotic pro-
grams [174,197,198]. Moderate rise in physiological ROS, on the
contrary are associated with the modification of pro-apoptotic members
of the Bcl-2 family such as Bax or stress response proteins such as JNK
[199–201]. Nevertheless, a mild pro-oxidant physiological state has
been associated with the diametric inversion of a favourable micro-
environment for signal transduction, growth and development tending
to a pro-neoplastic phenotype [202–211]. Despite strong evidence fa-
voring a correlation between the cellular superoxide concentrations and
carcinogenesis, it is discerned that the superoxide anion seldom subsists
in its native form to react with biomolecules. It is, in fact dismutated
almost instantaneously to hydrogen peroxide at a reaction rate of
~1.6×109 M−1 s−1. Indeed, the superoxide anion reacts more readily,
by a degree of three orders with nitric oxide. However, this relatively
moderate paced dismutation of superoxide into hydrogen peroxide is
favoured owing to the large body of SOD enzymes in the different
cellular compartments [196].
Hydrogen peroxide can impact signaling pathways through the se-
lective oxidation of cysteine moieties of member proteins constituting
these nodes, resulting in conformational changes to their structure and
function [212–214]. Au contraire, hydroxyl radical generated as a re-
sult of Fenton reaction in the presence of ferrous or cuprous ions leads
to multifarious destruction of nucleic acid, lipid and protein biomole-
cules [215,216]. As mentioned earlier, apart from getting dismutated to
hydrogen peroxide, the superoxide anion may also react readily with
nitric oxide physiologically to generate reactive nitrogen species. One
of the most biologically reactive notable species in this regard is the
peroxynitrite radical which has been reported to effect the oxidation of
fatty acid molecules as well as antioxidant proteins including glu-
tathione, ascorbate (vitamin C) and tocopherol (vitamin E) [217–219].
Peroxynitrite is also known to induce the breakage of amino acid chains
of proteins, DNA strand breaks and lipid peroxidations that contribute
to various pathological conditions. [220–224]. Nonetheless, some of the
most impactful biological impact of peroxynitrite is extended through
its ability to impose covalent modifications on proteins that include
nitration at the ortho position of tyrosine residues on proteins, which
have come to be known as nitrotyrosine footprints or S-nitrosylation of
cysteine residues. Some notable examples include the tyrosine nitration
of the RAS signaling members ERK and AKT in endothelial cells and the
cysteine S-nitrosylation of c-Src, PTEN and AKT [225–229].
Fig. 3. Reactive oxygen and nitrogen species: Superoxide anion is formed when
molecular oxygen gains an electron and gets reduced. The source of electrons
can be leakage from the mitochondrial electron transport chain (ETC), NADPH
oxidase (NOX) or xanthine oxidase (XO). Superoxide is a short-lived ROS spe-
cies that is instantaneously either dismutated to hydrogen peroxide through the
activity of the enzyme SOD, or to RNS such as peroxynitrite through its reaction
with nitric oxide. As is evident, there is a competition between formation of
hydrogen peroxide and peroxynitrite in cells that is dictated by the balance
between the activities of the two enzymes NOS and SOD. Hydrogen peroxide
can further be fated to generate the highly reactive hydroxyl ions as a result of
the Haber Weiss reaction in the presence of Ferrous ions or the biologically
reactive hypochlorous acid. The activity of the antioxidant catalase on hy-
drogen peroxide on the other hand detoxifies it to generate water.
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As mentioned earlier, ROS is observed to play a biphasic role in
cancer progression with respect to the nature of the ROS species, its
physiological location and concentration in the cell. While ROS gen-
eration through chemotherapeutic agents can be tailored as a ther-
apeutic window in some cancers to induce cell death, most usually by
targeting the antioxidant backbone of tumor cells, they can alter-
natively contribute to the selective survival of cancer cells and con-
tribute to tumor sustenance and progression [230–249]. In this context,
we have reported a novel role for peroxynitrite generated when the
balance between the enzymes SOD and iNOS is tilted in favour of iNOS
mediated RNS signaling. In this regard, we demonstrated the ability of
peroxynitrite to accentuate the anti-apoptotic response mediated by
Bcl-2 through its sustained phosphorylation at serine 70 residue, which
was a function of tyrosine nitration-mediated inactivation of phospha-
tase PP2A [242]. It is vital to note that the B56δ regulatory isoform of
PP2A, which we demonstrated to be nitrated by peroxynitrite, is not the
singular nitration labile arm of PP2A. Indeed, we suspect the analogous
tyrosine nitration of other B56 residues of PP2A, opening up a new
avenue in the field of the redox regulation of the cancer phosphatase
proteome.
As already elucidated, ROS mediated regulation of PP2A, albeit
indirect, will have considerable implications on the cancer proteome
through its impact on the regulation of PP2A substrates.
Serendipitously, other research groups have also identified ROS-medi-
ated modulation of PP2A activity and its impact on its substrates. For
instance, it has been proposed that hydrogen peroxide exposure of
primary neurons and neuronal cell lines as well as sarcoma cells results
in sustained activation of mitogen activated protein kinase (MAPK) via
the tyrosine phosphorylation and leucine carboxy-demethylation of
PP2A, which subsequently results in neuronal apoptosis and decrease in
cell viability of sarcoma cells, respectively [250,251]. Lending further
support to this theory, another research team conscientiously studied
PP2A expression, localization and activity in cardiovascular pathologies
and described the inhibitory effect of hydrogen peroxide on PP2A ac-
tivity through the aforementioned post-translational modifications
[252]. Hydrogen peroxide has also been demonstrated to impede PP2A
phosphatase activity through regulation of the glutathione oxidation
which suggests that glutathionylation of PP2A is an important factor in
modulating PP2A activity in cells [253]. Paradoxically, it was also re-
ported that hydrogen peroxide could lead to PP2A activation leading to
the subsequent dephosphorylation of the pocket proteins pRb, p107 and
p130 [254]. In support of PP2A activation through hydrogen peroxide
build up in cancer cells, another group has reported that the combi-
nation of standard chemotherapeutics sorafenib and vorinostat in gas-
trointestinal cancer led to upregulation of PP2A activity as a function of
ceramide synthesis, a known PP2A activator [255].
There is little studied on the thiol oxidation of PP2A, but the reports
do concur that such oxidation potentiates a reversible inhibitory effect
on PP2A activity. Thiol oxidation of cysteine residues of proteins lead to
the reversible formation of disulphide bonds. In this regard, the cata-
lytic subunit of the phosphatase PP2A is known to contain a number of
cysteine residues. Indeed, one such vicinal pair towards the C terminal
end at positions 266 and 269 of PP2A C is particularly noteworthy as it
comprises the redox sensitive CXXC motif, which is especially suscep-
tible to oxidative modifications leading to the formation of disulphide
bonds. Two studies have reported the oxidative modification of PP2A
leading to the inhibition of its activity, which can be effectively relieved
by mild concentrations of the thiol reducing agent, dithiothreitol (DTT)
[256,257]. However, the exact nature of such modification needs to be
studied in greater detail. For instance, the physical formation of dis-
ulphide bonds by mass spectrometry, the mapping of disulphide bonds
formation to a specific PP2A subunit and pinpointing the residues in-
volved in such redox targeting are urgent to fully understand the nature
of thiol oxidation on PP2A conformation and activity.
Reactive nitrogen species have also been reported to definitively
impact PP2A holoenzyme assembly and activity. For instance, nitric
oxide signaling has been reported by multiple research groups to
modulate PP2A activity through post-translational modifications ef-
fected on the catalytic subunit C-terminal tail. Contrary to nitric oxide
mediated activation of the catalytic subunit [171,258–260]. Low et al.
further report that peroxynitrite, a key reactive nitrogen species formed
through the association of the superoxide radical with nitric oxide, is
instead responsible for the nitration mediated inactivation of PP2A by
preventing the assembly of the PP2A holoenzyme [242].
Several reports have also suggested an integral role for hypoxic
microenvironments in modulating PP2A activity. For example,
Heikkinen et al. demonstrate that the hypoxic microenvironment is able
to increase PP2A activity through facilitating its interaction with Smad3
and its subsequent dephosphorylation [261]. Correspondingly, Conza
et al. mechanistically demonstrated that a hypoxic microenvironment
levies restraint on the mTOR signaling pathway rendering p70S6K in-
capable of inhibiting PP2A, subsequently leading to sustaining PHD2
phosphorylation in colorectal cancer cells [262]. In stark contrast to the
above observations, Raghuraman et al. argue that chronic intermittent
hypoxia exposure leads to inhibition of PP2A activity alongside a
concomitant decrease in PP2A C expression [263]. The above points
illustrate the important context of the physiological concentrations and
tissue specific biphasic nature of ROS.
6. Concluding remarks
Three decades after the first studies on the recognition of PP2A as a
tumor suppressor following the discovery of the marine toxin okadaic
acid and its role in tumor progression, we are at the threshold of tar-
geting PP2A regulation as a window into treatment of pathologies
where the phosphatase has been effectively demonstrated to regulate
key signaling proteins. Small molecules such as FTY720, OP-449 and
SMAPs are marking a milestone in the development of therapeutic
strategies to target physiological PP2A reactivation in cancers where its
expression and activity may be compromised.
At the same time, it is imperative to retain caution when strate-
gizing therapeutic interventions tailored to modulate PP2A activity as
the predominant perspective for this phosphatase to be analogous to a
tumor suppressor is short-sighted. This hypothesis was first challenged
on the basis of the anti-apoptotic role of PP2A in Drosophila melanoga-
ster demonstrated by two independent research groups in the early
years of the 21st century [264,265]. Secondly, some studies have un-
covered a positive correlation between PP2A subunits expression and
cancer aggressiveness, suggesting a complex dual personality for the
PP2A phosphatase as an oncogenic driver in these circumstances
[265–267]. Moreover, several compounds that are potent inhibitors of
PP2A activity such as Canthardin, Cytostatin, LB1.2 as well as the small
molecule compound LB-100 have shown promising results in alle-
viating tumor promoting phenotypes with the latter compound LB-100,
already endorsed in an active clinical trial against glioblastoma and
Table 1
ROS and PP2A interplay: A summary of the different ROS mediated functional
impact on PP2A expression, holoenzyme assembly and activity.
ROS milieu Targeted PP2A
subunit
Functional impact References
Hydrogen
peroxide
PP2A C Inactivation [250–252]
Unknown Activation [254,255]
PP2A
immunocomplex
Inactivation [253]
Thiol oxidation PP2A C/Unknown Inactivation [256,257]
Hypoxia PP2A A Activation [258]
PP2A B55α Activation [259]
PP2A C Inactivation by loss
of expression
[260]
Nitric oxide PP2A C Activation [171,261–263]
Peroxynitrite PP2A B56δ Inactivation [242]
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gliosarcoma (NCT03027388) [268–274]. Lenalidomide is another
therapeutic FDA approved compound that has already been demon-
strated to treat 5q del subset of myelodysplastic syndrome mechan-
istically through its inhibition of PP2A phosphatase. It concurrently,
has been reported to activate NK signaling and inhibition of pro-sur-
vival cytokines such as IL-6, leading to marked remission of multiple
myeloma [275,276].
Further development and favourable co-treatment strategies of
these compounds or tailoring the redox microenvironment to facilitate
PP2A modulation alongside the current standards of therapeutic in-
tervention are likely to improve the prognostic states of patients suf-
fering not only from cancers, but other debilitating pathologies where
PP2A is a core mediator of the signaling circuitry.
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